Apollo Hospitals Enterprise Limited (APOLLOHOSP) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Apollo Hospitals Enterprise Limited stock ₹5,234, price ₹8,371, that is 37.5% below the price, quality 58 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 1, 2026.
How to read this chart
60‑month range ₹3,481 – ₹9,069 · fair‑value band ₹2,615 – ₹6,685 · the ₹8,371 price screens above the ₹5,234 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 1, 2026.
Follow Apollo Hospitals Enterprise in your weekly email
Every Wednesday you see whether Apollo Hospitals Enterprise is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Apollo Hospitals Enterprise Limited, together with its subsidiaries, provides healthcare services in India. It operates through Healthcare Services, Retail Health & Diagnostics, Digital Health & Pharmacy Distribution, and Others segments.
Show moreShow less
The company's healthcare facilities comprise primary, secondary, and tertiary care, as well as specialty facilities.
It offers services in cardiac sciences, oncology, neurosciences, gastroenterology, orthopedics, urology, organ transplantation, pulmonology, obstetrics and gynecology, internal medicine, vascular surgery, pediatrics, cosmetology, emergency medicine, bariatric surgery, general surgery, colorectal surgery, dentistry, nephrology, dermatology, endocrinology, preventive medicine, interventional radiology, ophthalmology, and integrative medicine, as well as robotic surgery and genomics.
The company also provides project consultancy, medical educational institutes, Medvarsity for e-learning, and research services, as well as acts as an agent for life, general, and health insurance.
In addition, it operates hospitals, pharmacies, primary care clinics, and diagnostic centers; short stay facilities, boutique birthing centers, multi-specialty clinics, dental and dialysis facilities, and preventive care; day surgery, diabetes management, and cradle and fertility centers; and Apollo 24/7, a digital health mobile platform that provides teleconsultations, online pharmacy deliveries, home diagnostics, and insurance services.
Further, the company engages in the business of bio-banking of tissues. It serves patients, corporate clients, and the government and public sectors. Apollo Hospitals Enterprise Limited was incorporated in 1979 and is based in Chennai, India.
Stock analysis
Apollo Hospitals Enterprise Limited (APOLLOHOSP) currently trades at ₹8,371, while our model-based Fair Value estimate is ₹5,234, 37% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹3,337 per share, and 0 of the 26 models we run sit above the ₹8,371 price.
Bear case: the Economic Profit group reads lowest at ₹1,120, and 26 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹2,615 (bear) to ₹6,685 (bull), the price of ₹8,371 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Apollo Hospitals Enterprise Limited reported revenue of ₹252B in FY2026 versus ₹147B in FY2022, a compound +14.5%/yr. Reported net income was ₹19.4B in FY2026, compounding +16.5%/yr from FY2022.
Key figures
Market cap ₹1.2T (≈ $12.7B) Large · P/E ratio 57.6 · P/S ratio 4.55 · EPS (TTM) ₹145.26 · Dividend yield 0.2% · Net margin 7.9% · Return on equity 21.5% · Return on assets (EBIT) 29.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (low confidence).
What moves the price
The share trades about 8% below its 52-week high and 23% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −3% fair-value upside, at −37%, APOLLOHOSP screens richer than that median.
Fair Value models
Bear₹2,615Fair Value ₹5,234Bull₹6,685
Price ₹8,371 · Downside -37.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹75.50 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF₹832.25₹1,501₹3,08975
Growth DCF₹800.30₹1,588₹2,72875
EPV₹1,218₹1,408₹1,56874
All 26 models by family
DCF Models
FCF DCF₹832.25₹1,501₹3,08975
Owner Earnings₹457.07₹973.51₹1,89072
5Y Revenue Exit₹1,453₹3,061₹5,41069
5Y EBITDA Exit₹1,952₹4,178₹7,19372
5Y P/E Exit₹1,621₹3,437₹5,68668
10Y Revenue Exit₹1,160₹2,588₹5,09962
10Y EBITDA Exit₹1,544₹3,395₹6,62064
10Y P/E Exit₹1,330₹2,860₹5,33460
Earnings-Based
Graham-Dodd₹918.29₹5,517₹7,68963
Lynch FV₹1,573₹2,247₹2,92161
PEG = 1.0₹1,573₹2,247₹2,92157
EPV₹1,218₹1,408₹1,56874
Dividend Discount
Gordon GGM₹163.33₹305.77₹435.4867
DDM Multi-Stage₹163.33₹273.63₹325.2567
Multiples
P/E Multiple₹2,228₹2,971₹3,71463
P/S Multiple₹1,722₹2,296₹2,87058
P/B Multiple₹1,927₹2,569₹3,21155
EV/EBIT₹2,053₹2,908₹3,76365
EV/EBITDA₹2,240₹3,157₹4,07567
EV/Revenue₹1,318₹2,103₹2,88853
Asset-Based
NCAV (Graham)₹285.44₹382.49₹570.8854
Growth DCF
Growth DCF₹800.30₹1,588₹2,72875
Rev-Margin DCF₹1,453₹2,973₹5,11970
Economic Profit
Residual Income₹790.93₹1,120₹2,06972
ROIC Compounder₹1,441₹1,998₹2,73371
Growth Earnings
Growth-Adj P/E₹2,336₹3,337₹4,33867
The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+15.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.0%
Start year 2021 (pandemic). Over 10 years: +15.0% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.9%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+34.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+34.3%
Dividend (yield on the price)0.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.32.8% vs 23.0%, picking up
Profit margin 2005 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 12%
2026 sits 116% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+55.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+15.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +49.2% a year for the price and +11.2% for the forecasts.
Compare Apollo Hospitals Enterprise Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 235 stocks
Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside−37.5% · Bottom 25%
Profitability
Return on equity (12 months)21.5% · Top 25%
Return on assets8.8% · Top 25%
Net margin (12 months)7.9% · Above median
Operating margin (12 months)12.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)20.6% · Top 25%
Dividend yield (12 months)0.2% · Bottom 25%
Balance sheet
Debt / equity0.26× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)57.6× · Priciest 25%
P/B12.70× · Priciest 25%
P/S (12 months)4.55× · Priciest 25%
Price / free cash flow169.0× · Priciest 25%
EV/EBITDA32.9× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 35
FUTURE (revenue growth)100· sector 29
PAST (return on equity)86· sector 33
HEALTH (low debt)87· sector 90
DIVIDEND (yield)5· sector 40
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Apollo Hospitals Enterprise Limited (APOLLOHOSP) overvalued or undervalued?
As of Nov 1, 2026, our model estimates a fair value of ₹5,234 versus a price of ₹8,371, about 37% lower (overvalued).
What is the fair value of APOLLOHOSP?
Our model-based fair value for Apollo Hospitals Enterprise Limited is ₹5,234 (as of Nov 1, 2026), built from audited fundamentals. The current price: ₹8,371.
What is the quality score of APOLLOHOSP?
Apollo Hospitals Enterprise Limited has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
Our model-based price target is the fair value of ₹5,234 (as of Nov 1, 2026) from 26 valuation models. Cautious scenario ₹2,615, optimistic scenario ₹6,685. It is a calculation from audited fundamentals, not an analyst target.
What is the Apollo Hospitals Enterprise Limited stock forecast for 2026?
Our models put fair value at ₹5,234, about 37% lower versus a price of ₹8,371 (overvalued). Cautious scenario ₹2,615, optimistic scenario ₹6,685. The calculation is refreshed regularly with new filings.
What is the revenue of Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
Apollo Hospitals Enterprise Limited reported trailing-twelve-month revenue of about ₹264B (latest available figure, as of Nov 1, 2026).
Does Apollo Hospitals Enterprise Limited pay a dividend?
Apollo Hospitals Enterprise Limited currently shows a dividend yield of 0.24% relative to its recent price (as of Nov 1, 2026).
What growth is priced into Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
For today's price to be fair in a discounted-cash-flow model, Apollo Hospitals Enterprise Limited would have to grow free cash flow by +55.4 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +19.0 % per year. As of Nov 1, 2026.
What discount rate (WACC) does the fair value of APOLLOHOSP use?
Our models discount Apollo Hospitals Enterprise Limited at 10.4 %: a base by market capitalisation (large), damped by beta 0.18, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Apollo Hospitals Enterprise Limited that is +55.4 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Apollo Hospitals Enterprise Limited (APOLLOHOSP) delivered so far?
Over the past 5 years revenue at Apollo Hospitals Enterprise Limited grew +19.0 % a year. The price currently implies +55.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Apollo Hospitals Enterprise Limited (APOLLOHOSP) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Apollo Hospitals Enterprise Limited (+55.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
The free-cash-flow yield on the price is 0.59 %: that much free cash flow Apollo Hospitals Enterprise Limited produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Apollo Hospitals Enterprise Limited it is ₹5,234 per share (as of Nov 1, 2026), against a price of ₹8,371. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Apollo Hospitals Enterprise Limited stock overvalued or undervalued in 2026?
As of Nov 1, 2026, APOLLOHOSP trades above its calculated fair value: price ₹8,371, fair value ₹5,234, a gap of about −37% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of APOLLOHOSP?
No. The price is what the market pays today (₹8,371); the fair value is what the company's own numbers justify (₹5,234). For Apollo Hospitals Enterprise Limited the two are ₹3,137 per share apart. That gap is exactly why we show both numbers side by side.
How much is Apollo Hospitals Enterprise Limited worth?
The market values Apollo Hospitals Enterprise Limited at about ₹1.2T (market capitalisation, as of Nov 1, 2026). Per share that is ₹8,371; our models calculate a fair value of ₹5,234 per share.
What do the bullish and bearish scenarios say about APOLLOHOSP?
Our models span a range for Apollo Hospitals Enterprise Limited: cautious scenario ₹2,615, base ₹5,234, optimistic ₹6,685 per share (as of Nov 1, 2026, price ₹8,371). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of APOLLOHOSP?
Apollo Hospitals Enterprise Limited trades at a price-to-earnings ratio of 57.6 (as of Nov 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹5,234 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings, FY2026 ex one-offs: 71.5. Other multiples: P/B 12.7, P/S 4.6, EV/EBITDA 32.9.
How solid is the balance sheet of Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
Balance-sheet figures for Apollo Hospitals Enterprise Limited (as of Nov 1, 2026): return on equity 21.5%, debt of 0.26 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is APOLLOHOSP from its 52-week high?
Apollo Hospitals Enterprise Limited trades at ₹8,371, about 8% below its 52-week high of ₹9,069 and 23% above the low of ₹6,784 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of ₹5,234 is for.
Which stocks are comparable to Apollo Hospitals Enterprise Limited?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Apollo Hospitals Enterprise Limited stock attractive at the current price?
The data as of Nov 1, 2026: price ₹8,371, calculated fair value ₹5,234 (−37%), Quality Score 58/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of APOLLOHOSP calculated?
We run Apollo Hospitals Enterprise Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹5,234, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Apollo Hospitals Enterprise Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
The closing price on Nov 5, 2026 was ₹8,371. Our model-based fair value is ₹5,234, about 37% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Apollo Hospitals Enterprise Limited right now?
The price sits above even our optimistic bull case (₹6,685). The favourable scenario is already priced in. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹2,615 to ₹6,685) leaves room in how you read the outcome.
Where does the earnings growth of Apollo Hospitals Enterprise Limited (APOLLOHOSP) come from?
Earnings per share at Apollo Hospitals Enterprise Limited grew +20.1 % a year from 2015 to 2026. Broken into its drivers: revenue per share +14.7 %, EBIT margin −1.7 %, tax rate +0.2 %, residual (interest, one-offs) +6.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Apollo Hospitals Enterprise Limited
How large is the market capitalisation of Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
The market capitalisation of Apollo Hospitals Enterprise Limited is ₹1.2T (≈ $12.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
The price-to-sales ratio of Apollo Hospitals Enterprise Limited is 4.55 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
Earnings per share at Apollo Hospitals Enterprise Limited are ₹145.26 (price ÷ EPS = P/E 57.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
The dividend yield of Apollo Hospitals Enterprise Limited is 0.2% (payout 13.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
The net margin of Apollo Hospitals Enterprise Limited is 7.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
The return on equity (ROE) of Apollo Hospitals Enterprise Limited is 21.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
On an EBIT basis the return on assets of Apollo Hospitals Enterprise Limited is 29.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
The operating margin of Apollo Hospitals Enterprise Limited is 12.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
Revenue at Apollo Hospitals Enterprise Limited is growing +20.6% versus a year earlier (3y avg +14.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Apollo Hospitals Enterprise Limited (APOLLOHOSP)?
Earnings per share at Apollo Hospitals Enterprise Limited are growing +34.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Apollo Hospitals Enterprise Limited (APOLLOHOSP) carry?
The net debt of Apollo Hospitals Enterprise Limited is ₹73.8B (fiscal year 2026, ≈ 10.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Apollo Hospitals Enterprise Limited in the live analysis
One click puts Apollo Hospitals Enterprise Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 1, 2026